Plain-English translation of NCT04774419 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether — a type of immunotherapy drug that helps your immune system fight cancer — works better when combined with radiation therapy for women who have had surgery for advanced endometrial cancer. The study is specifically designed for cancers with certain genetic characteristics (called MMR-deficient or microsatellite instability-high) that may respond particularly well to this type of treatment. Researchers want to see if this combination can prevent the cancer from coming back after surgery.
Advanced endometrial cancer after surgery carries a high risk of recurrence, and current standard treatments don't work well enough for everyone. This medication has shown promise in treating certain types of endometrial cancer, so doctors want to test whether combining it with radiation — the standard treatment after surgery — could improve outcomes and give patients a better chance of long-term remission.
You likely qualify if…
You likely don't qualify if…
You would receive radiation therapy to the pelvic area over either 5-6 weeks (standard approach) or just one week (shorter approach), depending on which group you're in. At the same time, you'll receive infusions of the immunotherapy medication every 3 weeks for up to 5 doses total. The entire treatment course takes about 5-6 weeks (or one week plus follow-up infusions if you're in the shorter radiation group). You'll have regular clinic visits for treatment, blood work, and check-ins to monitor how you're tolerating the therapy.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States